Cargando…

Clinical Perspectives of ERCC1 in Bladder Cancer

ERCC1 is a key regulator of nucleotide excision repair (NER) pathway that repairs bulky DNA adducts, including intrastrand DNA adducts and interstrand crosslinks (ICLs). Overexpression of ERCC1 has been linked to increased DNA repair capacity and platinum resistance in solid tumors. Multiple single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koutsoukos, Konstantinos, Andrikopoulou, Angeliki, Dedes, Nikos, Zagouri, Flora, Bamias, Aristotelis, Dimopoulos, Meletios-Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700570/ https://www.ncbi.nlm.nih.gov/pubmed/33266377 http://dx.doi.org/10.3390/ijms21228829

Ejemplares similares

Defining Oligometastatic Bladder Cancer: A Systematic Review
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group
por: Bamias, Aristotelis, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
por: Liontos, Michalis, et al.
Publicado: (2021)

Supportive medication in cancer during pregnancy
por: Zagouri, Flora, et al.
Publicado: (2020)

Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Correction to: Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer
por: Skafida, Efthymia, et al.
Publicado: (2020)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

Germline mutations in a clinic-based series of pregnancy associated breast cancer patients
por: Zografos, Eleni, et al.
Publicado: (2021)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
por: Kyriazoglou, Anastasios, et al.
Publicado: (2018)

Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes
por: Dellis, Athanasios, et al.
Publicado: (2021)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
por: Gavalas, Nikos G., et al.
Publicado: (2010)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h0e8rcs53rphb7l1as060l2u2p